case_images: PMC5937482_01
case_images: (A) The PDGFR-beta expression in dermatofibrosarcoma protuberans (DFSP) by immunohistochemical staining in our case (100x and 400x original). PDGFR-beta is diffuse and strong staining in the paraffin-embedded tissue sample from our patient who received the sunitinib treatment. (B) Negative IHC staining of PDGFR-beta in another tissue sample from patient with DFSP. (C) Expression of COL1A1-PDGFB fusion transcripts. Ethidium bromide-stained agarose gel of reverse transcription polymerase chain reaction products from the paraffin-embedded tissue sample. (a) Amplification product of COL1A1 exon 43 forward primer and PDGFB exon 2 reverse primer yields a discrete band, indicating a breakpoint located downstream of COL1A1 exon 43. (b) The internal control is verified by amplification of beta-actin gene. (D) Nucleotide sequence analysis showing COL1A1-PDGFB fusion transcripts. The panel shows the nucleotide sequence of COL1A1-PDGFB fusion transcripts. The end of exon 44 in the COL1A1 gene was fused with the start of exon 2 in the PDGFB gene detected in the tissue sample.. Abbreviations: PDGFR, platelet-derived growth factor receptor; IHC, immunohistochemistry.
case_images: ott-11-2439Fig1.jpg
case_images: PMC5937482_01_ott-11-2439Fig1.jpg
case_images: f1-ott-11-2439
case_images: The experimental results showed the COL1A1-PDGFB fusion transcripts and over-expression of PDGFR-beta in paraffin-embedded samples of this patient (Figure 1).
case_images: The regular CT scan before and after sunitinib treatment. Radiology of pretreatment (A) and post-treatment (B) findings in our patient under sunitinib treatment.. Notes: (A) Baseline with evidence of lung (right red arrow) and pancreas (left red arrow) metastases before starting sunitinib. (B) Evidence of decrease in tumor size on regular scan after 3 months of sunitinib treatment.
case_images: ott-11-2439Fig2.jpg
case_images: PMC5937482_01_ott-11-2439Fig2.jpg
case_images: f2-ott-11-2439
case_images: The tumor size on the left upper arm was shrinking and a regular CT/MRI scan showed partial response in the lung and pancreas metastases over 2 months from initiation of sunitinib (35 months after initial diagnosis) (Figure 2).